The board of directors of Medtronic (NYSE:MDT) approved the company’s cash dividend for the second quarter of fiscal year 2027 of 72¢ per ordinary share.
This quarterly declaration is consistent with the dividend increase announcement made by the company in June 2026. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 49 consecutive years. The dividend is payable on Oct. 16, 2026, to shareholders of record at the close of business on Sept. 25, 2026.
Medtronic saw year-over-year revenue growth of 9.9% in the fourth quarter of its most recent fiscal year, with sales for the full year up 8.4%. It was the Minnesota-run medtech giant’s best quarterly revenue growth in 10 years.
Medtech pay analysis at Medical Design & Outsourcing: Medtronic increases pay for top executives and the median employee
Needham & Co. analysts said at the time that they see Medtronic in the early stages of a strong product cycle that will drive faster organic revenue growth. AFib-treating cardiac ablation has been a standout performer, with strong commercial demand for the Affera Sphere-9 pulsed field ablation catheter. The Affera system won an expanded indication for ventricular tachycardia (VT) and premature ventricular complexes (PVCs) in the EU earlier this month.
Medtronic officials are also excited about the growth potential of the company’s Symplicity Spyral renal denervation system for uncontrolled hypertension. The company is seeking expanded U.S. indications for its Hugo robotic surgery system as it takes on Intuitive in the soft-tissue surgical robotics space, and there’s excitement around the Altaviva implantable tibial neuromodulation for urge urinary incontinence and the Stealth AXiS robotic spine surgery system, which earned a CE mark for ENT surgery earlier this summer.
Medtronic has also resumed mergers and acquisitions this year, announcing a string of purchases including $650 million for SPR Therapeutics and its percutaneous peripheral nerve stimulation therapies for chronic pain management, $550 million for Scientia Vascular and its products for treating complex neurovascular conditions, and $585M for CathWorks and its FFRangio system meant to obtain quick and reliable fractional flow reserve.
“We executed our focused portfolio strategy. In early March, we completed the Minimed [diabetes business] IPO, establishing it as a standalone, publicly traded [diabetes tech] company. We also advanced our M&A and venture initiatives, targeting higher growth segments to accelerate innovation in markets where we have a right to win,” CEO Geoff Martha said.
Medtronic reports first quarter results on Sept. 1.
Editor-in-chief Chris Newmarker contributed to this report.
